Cargando…
De Novo design of potential inhibitors against SARS-CoV-2 Mpro
The impact of the ravages of COVID-19 on people's lives is obvious, and the development of novel potential inhibitors against SARS-CoV-2 main protease (Mpro), which has been validated as a potential target for drug design, is urgently needed. This study developed a model named MproI-GEN, which...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197785/ https://www.ncbi.nlm.nih.gov/pubmed/35763931 http://dx.doi.org/10.1016/j.compbiomed.2022.105728 |
_version_ | 1784727491110240256 |
---|---|
author | Li, Shimeng Wang, Lianxin Meng, Jinhui Zhao, Qi Zhang, Li Liu, Hongsheng |
author_facet | Li, Shimeng Wang, Lianxin Meng, Jinhui Zhao, Qi Zhang, Li Liu, Hongsheng |
author_sort | Li, Shimeng |
collection | PubMed |
description | The impact of the ravages of COVID-19 on people's lives is obvious, and the development of novel potential inhibitors against SARS-CoV-2 main protease (Mpro), which has been validated as a potential target for drug design, is urgently needed. This study developed a model named MproI-GEN, which can be used for the de novo design of potential Mpro inhibitors (MproIs) based on deep learning. The model was mainly composed of long-short term memory modules, and the last layer was re-trained with transfer learning. The validity (0.9248), novelty (0.9668), and uniqueness (0.0652) of the designed potential MproI library (PMproIL) were evaluated, and the results showed that MproI-GEN could be used to design structurally novel and reasonable molecules. Additionally, PMproIL was filtered based on machine learning models and molecular docking. After filtering, the potential MproIs were verified with molecular dynamics simulations to evaluate the binding stability levels of these MproIs and SARS-CoV-2 Mpro, thereby illustrating the inhibitory effects of the potential MproIs against Mpro. Two potential MproIs were proposed in this study. This study provides not only new possibilities for the development of COVID-19 drugs but also a complete pipeline for the discovery of novel lead compounds. |
format | Online Article Text |
id | pubmed-9197785 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91977852022-06-15 De Novo design of potential inhibitors against SARS-CoV-2 Mpro Li, Shimeng Wang, Lianxin Meng, Jinhui Zhao, Qi Zhang, Li Liu, Hongsheng Comput Biol Med Article The impact of the ravages of COVID-19 on people's lives is obvious, and the development of novel potential inhibitors against SARS-CoV-2 main protease (Mpro), which has been validated as a potential target for drug design, is urgently needed. This study developed a model named MproI-GEN, which can be used for the de novo design of potential Mpro inhibitors (MproIs) based on deep learning. The model was mainly composed of long-short term memory modules, and the last layer was re-trained with transfer learning. The validity (0.9248), novelty (0.9668), and uniqueness (0.0652) of the designed potential MproI library (PMproIL) were evaluated, and the results showed that MproI-GEN could be used to design structurally novel and reasonable molecules. Additionally, PMproIL was filtered based on machine learning models and molecular docking. After filtering, the potential MproIs were verified with molecular dynamics simulations to evaluate the binding stability levels of these MproIs and SARS-CoV-2 Mpro, thereby illustrating the inhibitory effects of the potential MproIs against Mpro. Two potential MproIs were proposed in this study. This study provides not only new possibilities for the development of COVID-19 drugs but also a complete pipeline for the discovery of novel lead compounds. Elsevier Ltd. 2022-08 2022-06-15 /pmc/articles/PMC9197785/ /pubmed/35763931 http://dx.doi.org/10.1016/j.compbiomed.2022.105728 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Li, Shimeng Wang, Lianxin Meng, Jinhui Zhao, Qi Zhang, Li Liu, Hongsheng De Novo design of potential inhibitors against SARS-CoV-2 Mpro |
title | De Novo design of potential inhibitors against SARS-CoV-2 Mpro |
title_full | De Novo design of potential inhibitors against SARS-CoV-2 Mpro |
title_fullStr | De Novo design of potential inhibitors against SARS-CoV-2 Mpro |
title_full_unstemmed | De Novo design of potential inhibitors against SARS-CoV-2 Mpro |
title_short | De Novo design of potential inhibitors against SARS-CoV-2 Mpro |
title_sort | de novo design of potential inhibitors against sars-cov-2 mpro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197785/ https://www.ncbi.nlm.nih.gov/pubmed/35763931 http://dx.doi.org/10.1016/j.compbiomed.2022.105728 |
work_keys_str_mv | AT lishimeng denovodesignofpotentialinhibitorsagainstsarscov2mpro AT wanglianxin denovodesignofpotentialinhibitorsagainstsarscov2mpro AT mengjinhui denovodesignofpotentialinhibitorsagainstsarscov2mpro AT zhaoqi denovodesignofpotentialinhibitorsagainstsarscov2mpro AT zhangli denovodesignofpotentialinhibitorsagainstsarscov2mpro AT liuhongsheng denovodesignofpotentialinhibitorsagainstsarscov2mpro |